Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | PBCAR0191 allo-CAR-T for ALL and NHL: preliminary findings

Bijal Shah • 10 Dec 2019
ASH 2019
Acute Lymphoblastic Leukemia Leukemia Lymphoma Non-Hodgkin Lymphoma CAR-T PBCAR0191

Bijal Shah, MD, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, discusses the initial findings of the phase 1 trial (NCT03666000) of PBCAR0191, an anti-CD19 allogeneic CAR T-cell product designed to reduce the risk of graft-versus-host disease (GvHD), which is a limitation of allogeneic products, in patients with relapsed/refractory acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL). Additionally, Dr Shah mentions the next steps in the dose-escalation study of safety of PBCAR0191. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Bijal Shah

1:33
The impact of prior therapies on the outcomes of patients with R/R ALL treated with CAR-T therapy
Bijal Shah • 8 Sep 2023
1:27
TP53-aberrant MCL: challenges and treatment approaches
Bijal Shah • 8 Sep 2023
1:03
ECOG-E1910 study: clinical benefit of early blinatumomab incorporation in ALL
Bijal Shah • 8 Sep 2023
1:03
An insight into the sequencing of immunotherapies in adults with ALL
Bijal Shah • 8 Sep 2023

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals